SCHEMBL21971002

SCHEMBL21971002

CN1Cc2ccc(Cl)cc2-c2cccnc2C1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PTAFR P25105 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
GABRG2 P18507 5/20 0.40
GABRB3 P28472 5/20 0.40
GABRA5 P31644 5/20 0.40
GABRA1 P14867 4/20 0.40
GABRA3 P34903 4/20 0.40
GABRA2 P47869 4/20 0.40
GABRA6 Q16445 4/20 0.40
FNTA P49354 2/20 0.40
FNTB P49356 2/20 0.40
GABRA4 P48169 2/20 0.40
MEN1 O00255 1/20 0.39
THRB P10828 1/20 0.39
BLM P54132 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP11B1 P15538 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21903297 0.81 MAP3K5 (0.47) MEN1THRBBLMKMT2ATDP1
SCHEMBL21970112 0.81 GABRG2 (0.40) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL21903324 0.80 GABRG2 (0.39) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL21970089 0.79 DPP4 (0.45) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL13213025 0.78 GABRG2 (0.47) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL21970099 0.78 DPP4 (0.42) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL21903237 0.77 PRF1 (0.40) GABRA1
SCHEMBL29986738 0.77 PRF1 (0.40) GABRA1
SCHEMBL21903321 0.76 DPP4 (0.40) GABRG2GABRB3GABRA5GABRA1GABRA3
SCHEMBL21903238 0.76 CYP11B2 (0.42) PTAFRRXFP1FNTAFNTBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11472806-B2 Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors DOMAIN THERAPEUTICS (FR) 2022-10-18 US disclosed
US-20200140438-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS DOMAIN THERAPEUTICS (FR) 2020-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200140438-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS GRM3, GRM1, GRM2 LMNA 4813/4885SMN1; SMN2 2598/4885PTAFR 1286/4885
US-11472806-B2 Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors GRM3, GRM1, GRM2 LMNA 4813/4885SMN1; SMN2 2598/4885PTAFR 1286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.